Slide 1: Investor Presentation 9M2025
Investor Presentation 9M2025 1
Slide 2: ISPH: Business Strategy
ISPH: Business Strategy Seizing every vertical and horizontal growth opportunity to realize higher revenues and profit margin, strengthening ties with suppliers and customers Customer Supplier Capturing Higher Margin Aligning Pharma Market Growth Opportunities Growth Opportunities (Core Business) Re
Slide 3: ISPH: Business Lines
ISPH: Business Lines 4 primary business services achieving growth and diversifying revenue streams for higher sustainability, leveraging 23-year experience in supply chain management. Pharma FMCG Medical 3PL & 4PL Distribution Distribution Promotions Services 2001 2022 2023 2021 57.4bn +45% 3.2bn +5
Slide 4: ISPH: Investment Catalysts 2025 - 2026
ISPH: Investment Catalysts 2025 - 2026 Unique business model representing an index to the Egyptian market with upside on multiple fronts. Only Proxy Change in Full Effect of for HC Competition Repricing Expenditure Landscape Normalization in units with higher ASP % Deleveraging Decrease in Higher th
Slide 5: Pharma Market: Total Pharma Market Growth
Pharma Market: Total Pharma Market Growth 35% Exchange Rate pressure EDA to increase Prices resulting in a double-digit growth in market value +29bn 25 QoQ Growth FY, 2022: 160bn FY, 2023: 206bn FY, 2024: 292bn 9M, 2025: 296bn 110 92 95 91 81 62 61 57 59 44 46 42 42 37 37 Q1, 2022 Q2, 2022 Q3, 2022
Slide 6: Pharma Market: Growth Drivers
Q3 2025 vs 2024 Pharma Market: Growth Drivers Units ASP Growth leveraged by “Average Selling Price” growth compensating decline in “Units sold” á 15% á 18% 114 0 0 .0 0 0 1 1 0 958 949 960 949 107 957 938 104 893 887 97 880 883 82% 0 0 1 836 833 96 0 0 8 . 0 0 0 809 815 796 0 9 % of Av. contribution
Slide 7: Performance Highlights: 9M, 2025
Performance Highlights: 9M, 2025 Key business highlights indicate positive trajectory on multiple fronts, emphasizing the positive performance of the current market leader in terms of growth, diversification and sustainable business practices. 30.9% 1 45% 63% 62% Market Growth in Growth in Growth in
Slide 8: Market Share: ISP Market Share based on Value
1 Market Share: ISP Market Share based on Value Leading the market half-way through 2025, retaining the position since 2023. Market Leader 9M 25 1.03% 0.3% Growth in MS: Value Growth in MS: Units 9M 2025 vs 9M 2024 9M 2025 vs 9M 2024 31.0% 31.3% 30.9% 0 % 3 0 % 3 29.8% 5 % 2 5 % 2 24.6% 23.9% 0 % 2
Slide 9: Consolidated Revenue Analysis: Growth
9M 25 vs 24 Unit G 9M 25 vs 24 Value G Consolidated Revenue Analysis: Growth Sustaining growth momentum YoY, staying well-above OPEX growth and 12% 45% capturing opportunities 93mn 18bn 2022 Revenue: 22.9bn | G: 2% 2023 Revenue: 35bn | G: 53% 2024 Revenue: 57.9bn | G: 65% 25 Revenue: 57.8bn 9M G: 0%
Slide 10: Pharma Revenue Analysis: Segments' Growth
Q3 25 vs 24 Value G Pharma Revenue Analysis: Segments’ Growth Addressing customer segments individually, achieving remarkable growth figures primarily 31% from cash segments 17.8bn 2022 Revenue: 22.8bn 2023 Revenue: 34.7bn 2024 Revenue: 57.5bn 2025 Revenue 9M: 16.1bn 9M: 24bn 9M: 39.6bn 9M: 57.4bn 2
Slide 11: Non-pharma Distribution: Revenue Analysis & Customer Portfolio
Non-pharma Distribution: Revenue Analysis & Customer Portfolio Non-pharma Distribution Business Model – Higher Margin Business Line with Great Potential – Picking up the pace, contributing with significance to bottom line The Business Revenue Growth Market Share Suppliers Market Share Free Pricing ,
Slide 12: Medical Promotion Review: Business Overview
Medical Promotion Review: Business Overview 41% Trending business model in the Egyptian market, adopted by most multinational supplier and in early Net Profit Margin adoption by local ones. Great potential, high synergy with distribution business and high NPM. 9M 2025 Medical Promotion Outsourcing O
Slide 13: Ramp Logistics Review: Service Outline & Top Line Overview
Ramp Logistics Review: Service Outline & Top Line Overview Positive performance on the top & bottom-line sides, achieving healthy growth levels vertically and horizontally, diversifying revenue streams for sustainability. Services Revenue Analysis P&L Client Portfolio 7 Sites, 40,000 PP Revenue Anal
Slide 14: Gross Profit: Gross Profit Analysis
Gross Profit: Gross Profit Analysis Achieving new heights of Gross Profit due to focus on CDG and GDT, ensuring sustainability of growth against rising economic challenges FY 2022: 1,617 FY 2023: 2,515 FY 2024: 4,397 9M 2025: 4,741 Cash Discount Given 7.6% 7.8% 7.8% 8.6% 9M GPM 9M GPM 9M GPM GPM -5%
Slide 15: OPEX Optimization: EBITDA-M vs OPEX to Sales
OPEX Optimization: EBITDA-M vs OPEX to Sales 58% 18% Cumulative EBITDA margin continues its steady incline against a steady OPEX : Sales Digital Sales Retail Sales Growth Share decline, reflecting effective optimization efforts, paving the way to a healthy bottom line 664mn 1,328mn 2,508mn FY EBITDA
Slide 16: Income Statement: 9M, 24 vs 25
Income Statement: 9M, 24 vs 25 ISP Consolidated 62% growth in NP collectively despite set-backs in subsidiaries performance and due to the solid position ISP Standalone of Ibnsina Pharma AIM Consolidated Gross Sales (Growth: 45 %) Gross Profit (Growth: 58%) OPEX (Growth: 51%) EBITDA (Growth: 63%) 57
Slide 17: Margin Analysis: GPM, EBITDA-M, EBIT-M, NPM
Margin Analysis: GPM, EBITDA-M, EBIT-M, NPM Healthy margin improvement across all lines with exceptional performance on EBITDA and NP levels 9M Margin Analysis 0.8% 2022 - 2025 8.6% 7.8% 7.8% 7.9% 7.6% 0.6% 0.6% 5.1% 53mn 12mn 4.5% 4.5% 4.6% FX Gain FX Gain 1.2bn 1.9bn 3bn 4.4bn 4.7bn 4.2% 2024 2025
Slide 18: Net Debt Optimization: Most Indicative Financial Ratios on Debt
Net Debt Optimization: Most Indicative Financial Ratios on Debt Debt levels rise due repricing impact, dictating quick collection and inventory management actions to mitigate associated risks. -0.7mn Net Debt Decrease Net Debt to Equity -0.5 Decrease Tender Exposure 7.3 6.5 6.6 3.1 3.0 2.7 2.6 2.6 4
Slide 19: Financial Expenses: Debt Levels vs Interest Expense
Financial Expenses: Debt Levels vs Interest Expense 1.9bn 2.8bn Healthy spread maintained between EBITDA and Financial Expenses at 1.4% Financial Exp. EBITDA 9M 2025 9M 2025 despite repricing effect on working capital. 9M Int: 322mn | EBITDA: 495mn 9M Int: 743mn | EBITDA: 993mn 9M Int: 1.2bn| EBITDA
Slide 20: Guidance: Key P&L & B/S Metrics
Guidance: Key P&L & B/S Metrics EGP 2,433mn EGP 615mn % : Sales: 3.2% 2024A: 443mn Forecasted 2025 full-year performance SG&A (+768mn) CAPEX Assumptions 2025: 33.8% +2.7% 22.2bn 0 ,0 0 9 5 % 4 25% 0 ,0 0 8 Difference 0 % 4 , 0 0 7 2.0bn Difference 0 % 5 Market Growth 80,143 1.2bn (22% ASP, 3% Units)
Slide 21: ibnsinapharma
ibnsinapharma